344 related articles for article (PubMed ID: 21081214)
1. Vascular pharmacology of epoxyeicosatrienoic acids.
Pfister SL; Gauthier KM; Campbell WB
Adv Pharmacol; 2010; 60():27-59. PubMed ID: 21081214
[TBL] [Abstract][Full Text] [Related]
2. Epoxyeicosatrienoic acids and endothelium-dependent responses.
Campbell WB; Fleming I
Pflugers Arch; 2010 May; 459(6):881-95. PubMed ID: 20224870
[TBL] [Abstract][Full Text] [Related]
3. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease.
Elmarakby AA
Am J Physiol Regul Integr Comp Physiol; 2012 Feb; 302(3):R321-30. PubMed ID: 22116511
[TBL] [Abstract][Full Text] [Related]
4. Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function.
Imig JD
Prostaglandins Other Lipid Mediat; 2013; 104-105():2-7. PubMed ID: 23333581
[TBL] [Abstract][Full Text] [Related]
5. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition.
Larsen BT; Miura H; Hatoum OA; Campbell WB; Hammock BD; Zeldin DC; Falck JR; Gutterman DD
Am J Physiol Heart Circ Physiol; 2006 Feb; 290(2):H491-9. PubMed ID: 16258029
[TBL] [Abstract][Full Text] [Related]
6. Epoxyeicosatrienoic acid administration or soluble epoxide hydrolase inhibition attenuates renal fibrogenesis in obstructive nephropathy.
Noh MR; Jang HS; Salem FE; Ferrer FA; Kim J; Padanilam BJ
Am J Physiol Renal Physiol; 2023 Feb; 324(2):F138-F151. PubMed ID: 36475868
[TBL] [Abstract][Full Text] [Related]
7. Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation.
Oltman CL; Weintraub NL; VanRollins M; Dellsperger KC
Circ Res; 1998 Nov; 83(9):932-9. PubMed ID: 9797342
[TBL] [Abstract][Full Text] [Related]
8. Endothelium-independent, ouabain-sensitive relaxation of bovine coronary arteries by EETs.
Pratt PF; Li P; Hillard CJ; Kurian J; Campbell WB
Am J Physiol Heart Circ Physiol; 2001 Mar; 280(3):H1113-21. PubMed ID: 11179054
[TBL] [Abstract][Full Text] [Related]
9. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors.
Campbell WB; Gebremedhin D; Pratt PF; Harder DR
Circ Res; 1996 Mar; 78(3):415-23. PubMed ID: 8593700
[TBL] [Abstract][Full Text] [Related]
10. Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system.
Larsen BT; Campbell WB; Gutterman DD
Trends Pharmacol Sci; 2007 Jan; 28(1):32-8. PubMed ID: 17150260
[TBL] [Abstract][Full Text] [Related]
11. EET signaling in cancer.
Panigrahy D; Greene ER; Pozzi A; Wang DW; Zeldin DC
Cancer Metastasis Rev; 2011 Dec; 30(3-4):525-40. PubMed ID: 22009066
[TBL] [Abstract][Full Text] [Related]
12. CYP450 Epoxygenase Metabolites, Epoxyeicosatrienoic Acids, as Novel Anti-Inflammatory Mediators.
Shi Z; He Z; Wang DW
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744996
[TBL] [Abstract][Full Text] [Related]
13. Epoxyeicosatrienoic Acids and 20-Hydroxyeicosatetraenoic Acid on Endothelial and Vascular Function.
Imig JD
Adv Pharmacol; 2016; 77():105-41. PubMed ID: 27451096
[TBL] [Abstract][Full Text] [Related]
14. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function.
Spector AA; Fang X; Snyder GD; Weintraub NL
Prog Lipid Res; 2004 Jan; 43(1):55-90. PubMed ID: 14636671
[TBL] [Abstract][Full Text] [Related]
15. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.
Yu Z; Xu F; Huse LM; Morisseau C; Draper AJ; Newman JW; Parker C; Graham L; Engler MM; Hammock BD; Zeldin DC; Kroetz DL
Circ Res; 2000 Nov; 87(11):992-8. PubMed ID: 11090543
[TBL] [Abstract][Full Text] [Related]
16. Epoxide hydrolases regulate epoxyeicosatrienoic acid incorporation into coronary endothelial phospholipids.
Weintraub NL; Fang X; Kaduce TL; VanRollins M; Chatterjee P; Spector AA
Am J Physiol; 1999 Nov; 277(5):H2098-108. PubMed ID: 10564166
[TBL] [Abstract][Full Text] [Related]
17. Epoxyeicosatrienoic acid pathway in human health and diseases.
Bellien J; Joannides R
J Cardiovasc Pharmacol; 2013 Mar; 61(3):188-96. PubMed ID: 23011468
[TBL] [Abstract][Full Text] [Related]
18. Arachidonic acid cytochrome P450 epoxygenase pathway.
Spector AA
J Lipid Res; 2009 Apr; 50 Suppl(Suppl):S52-6. PubMed ID: 18952572
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha.
Ng VY; Huang Y; Reddy LM; Falck JR; Lin ET; Kroetz DL
Drug Metab Dispos; 2007 Jul; 35(7):1126-34. PubMed ID: 17431031
[TBL] [Abstract][Full Text] [Related]
20. 14,15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries.
Gauthier KM; Deeter C; Krishna UM; Reddy YK; Bondlela M; Falck JR; Campbell WB
Circ Res; 2002 May; 90(9):1028-36. PubMed ID: 12016270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
